KOSDAQCosmetics950140

Englewood Lab

₩5,960▼ 1.32%2026-11-18 close
Market Cap
₩118.4B
Turnover
₩100M
Volume
20K
Shares out.
19.9M
PER
6.9×
PBR
0.8×
EPS
₩910
Dividend Yield
3.21%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩201 per share · Prices as of the 2026-11-18 close

01

Report overview

Englewood Lab: 2025 Profit Rebound, Q3 2026 Net Loss

Englewood Lab's operating profit rose 90.7% to KRW 35.3 billion in 2025, but the company posted a controlling-shareholder net loss of KRW 1.35 billion in Q3 2026.

  1. 1

    Operating profit in 2025 was KRW 35.3 billion, up 90.7% year on year, and the operating margin of 17.2% was the highest in the 2022–2025 period.

  2. 2

    Controlling-shareholder net income swung to a loss of KRW 1.35 billion in Q3 2026, from a profit of KRW 10.7 billion a year earlier. Operating profit in the quarter was KRW 4.87 billion.

  3. 3

    Controlling-shareholder net income for the most recent four quarters (Q4 2025 to Q3 2026) totaled KRW 18.1 billion.

  4. 4

    On October 30, 2026, the company disclosed a plan for a year-end cash dividend of up to KRW 3 billion for fiscal 2026, with the final amount possibly lower.

  5. 5

    At year-end 2025 the debt-to-equity ratio was 37.9% and total equity stood at KRW 154.2 billion (KRW-converted), with leverage lower than the 51.1% recorded in 2023.

02

Business structure

Englewood Lab is an OEM and ODM contract manufacturer for cosmetics, handling product planning, formulation development, production and launch. Production sites are in the United States and Korea, and the company's Korean plant is located in Chungbuk.

Its Q3 2026 category mix was basic cosmetics at 69.2%, functional cosmetics and OTC products at 21.5%, makeup at 5.9% and other at 3.3%. In the US, the company promotes a one-stop OGM offering and targets independent brands in North America.

Its RTG OTC service supports sunscreen products classified as OTC drugs in the US, covering FDA guideline compliance through launch. A press report described Englewood Lab as a US subsidiary of Cosmecca Korea. The stock has been listed on KOSDAQ since October 14, 2016.

Peers in the domestic ODM market include Cosmax and Kolmar Korea, and Englewood Lab differentiates itself through its US production base and North American independent-brand focus.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩60B₩12.8B21.4%
2025Q4₩50.5B₩8.6B17.0%
2026Q1₩45.7B₩5.1B11.3%
2026Q2₩46.5B₩7.8B16.8%
2026Q3₩43.1B₩4.9B11.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩157.7B₩10.3B₩7.6B6.5%7.7%45.5%
2023₩213B₩29.7B₩21.4B14.0%17.8%51.1%
2024₩179.7B₩18.5B₩19.4B10.3%14.7%38.8%
2025₩205B₩35.3B₩23.5B17.2%15.2%37.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-10

04

Earnings analysis

On a KRW-converted basis (the company reports in USD), revenue rose from KRW 157.7 billion in 2022 to KRW 213 billion in 2023, up 35.1%, fell to KRW 179.7 billion in 2024, down 15.7%, and reached KRW 205 billion in 2025, up 14.1%. 2023 was the largest revenue year.

Operating profit moved from KRW 10.3 billion in 2022 to KRW 29.7 billion in 2023 (up 189.0%), KRW 18.5 billion in 2024 (down 37.7%) and KRW 35.3 billion in 2025 (up 90.7%), with 2025 the largest year. The operating margin was 6.5% in 2022, 14.0% in 2023, 10.3% in 2024 and 17.2% in 2025, the highest of the period.

Controlling-shareholder net income was KRW 7.56 billion in 2022, KRW 21.4 billion in 2023 (up 182.6%), KRW 19.4 billion in 2024 (down 9.4%) and KRW 23.5 billion in 2025 (up 21.2%).

Net income including non-controlling interests is reported at KRW 7.56 billion, KRW 21.4 billion, KRW 19.4 billion and KRW 23.5 billion for the same years. The debt-to-equity ratio rose from 45.5% in 2022 to 51.1% in 2023, then fell to 38.8% in 2024 and 37.9% in 2025.

Operating cash flow was KRW 10.1 billion, KRW 21.5 billion, KRW 12.7 billion and KRW 21 billion for 2022 through 2025, below operating profit in each of those years.

Quarterly revenue went from KRW 60 billion in Q3 2025 to KRW 50.5 billion in Q4 2025 (down 15.8% quarter on quarter), KRW 45.7 billion in Q1 2026 (down 9.7%), KRW 46.5 billion in Q2 2026 (up 1.8%) and KRW 43.1 billion in Q3 2026 (down 7.2%, down 28.1% year on year).

Operating profit went from KRW 12.8 billion in Q3 2025 to KRW 8.61 billion, KRW 5.14 billion and KRW 7.82 billion across the next three quarters, and then to KRW 4.87 billion in Q3 2026 (down 62.1% year on year). The weakness in Q3 2026 has been attributed to the Korean subsidiary EWLK.

In Q2 2025, EWLK reported operating profit of KRW 8.2 billion, showing that the subsidiary carries a large share of group profit. Average exchange rates applied in Q3 2026 were KRW 1,423.38 per dollar, above KRW 1,385.28 a year earlier.

05

Industry analysis

Englewood Lab manufactures products on behalf of brand owners as a contract manufacturer. In the same industry, Cosmax and Kolmar Korea are regarded as large domestic ODM companies, while Englewood Lab's focus is on US production and North American clients.

At the MakeUp in NewYork 2026 trade show held in September 2026, the company highlighted a custom strategy for North American independent brands and local manufacturing capacity that spans small-batch to large-volume runs.

The skincare-makeup hybrid formulations shown at the event combine high-functionality basic care with makeup expressiveness. The growing influence of independent brands in North America is a factor to watch for the company's client base.

Its OTC sunscreen entry support demonstrates regulatory capability in North America. In an earlier first-quarter results briefing from the period of expanding COVID-19 vaccinations, the company said that a shift from turnkey orders to OEM orders improved profitability.

Demand for consumer goods reaches the company through client order volumes. With basic cosmetics at 69.2% of Q3 2026 revenue, exposure to changes in basic-product demand is high. Competitive differentiation rests on the US production base and the OTC sunscreen service.

06

Outlook

The company plans to submit a proposal for a year-end cash dividend of up to KRW 3 billion for fiscal 2026 to its 2027 annual general meeting. The dividend is conditional on distributable profit being confirmed after the financial statements are finalized, with a record date of December 31, 2026.

The resolution will be denominated in US dollars, with the won-dollar rate at the time of resolution taken into account, and the final amount may fall short of KRW 3 billion.

On products, the RTG OTC sunscreen service drew interest from global buyers at Cosmoprof Las Vegas in July 2026 and at the New York show in September 2026. The company said it will develop new independent brands and deepen partnerships with global brands. The next checkpoint is the Q4 2026 provisional results.

The prior-year Q4 provisional results were disclosed on February 20, 2026, so a similar schedule would place them in mid-February 2027. The fiscal 2026 business report is due by late March 2027.

Whether EWLK's weakness in Q3 2026 persists after Q4, and whether operating margin recovers from the Q3 2026 level, are the key items to confirm.

07

Valuation

PER
6.9×
PBR
0.8×
ROE
11.5%
EPS
₩910
BPS
₩8,322
Dividend per share
₩201

Valuation levels move daily with the share price. On a book-value basis, market capitalization sits below year-end 2025 total equity of KRW 154.2 billion, which means the stock trades below 1x book value. That relationship reads as a discount to net assets, but it should be interpreted alongside the earnings trend.

Controlling-shareholder net income for the most recent four quarters totals KRW 18.1 billion, and the earnings base has weakened since the Q3 2026 net loss. Compared with controlling-shareholder net income of KRW 10.7 billion in Q3 2025, quarterly swings materially change how earnings multiples read.

The move from 2024 to 2025 shows a recovery, with the operating margin rising from 10.3% to 17.2%. A dividend of up to KRW 3 billion for fiscal 2026 has been disclosed, and the final amount will determine the shareholder return level. No historical valuation band comparison is presented here.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-10

08

Bull factors

Profitability recovery in 2025

Operating profit in 2025 was KRW 35.3 billion, up 90.7% year on year, and the 17.2% operating margin was the highest since 2022. The improvement from a 10.3% margin in 2024 is read as evidence of a stronger earnings structure. The subsidiary EWLK's KRW 8.2 billion operating profit in Q2 2025 also helped drive the expansion.

Shareholder return plan

The company plans a year-end cash dividend of up to KRW 3 billion for fiscal 2026. It cites maximizing shareholder returns and raising corporate value as the purpose. A debt-to-equity ratio that fell to 37.9% at year-end 2025 is the backdrop for the plan.

US production base and OTC service

The company emphasizes US infrastructure that covers small-batch to large-volume production. Its RTG OTC sunscreen service drew interest from global buyers at Cosmoprof Las Vegas in July 2026 and at the New York show in September 2026. The company has set new independent-brand development and stronger global-brand partnerships as priorities.

09

Bear factors

Sharp profit drop in Q3 2026

Operating profit in Q3 2026 was KRW 4.87 billion, down 62.1% year on year. Controlling-shareholder net income swung to a loss of KRW 1.35 billion from a profit of KRW 10.7 billion a year earlier. Operating profit also fell 37.7% from the prior quarter's KRW 7.82 billion.

Dependence on the subsidiary

The Q3 2026 decline has been attributed to weakness at the subsidiary EWLK. In Q2 2025, EWLK's operating profit of KRW 8.2 billion showed how large a share of group profit the subsidiary carries. Swings at the subsidiary pass directly into consolidated earnings, which raises volatility.

Slowing quarterly revenue

Quarterly revenue fell from KRW 60 billion in Q3 2025 to KRW 43.1 billion in Q3 2026. Apart from a 1.8% quarter-on-quarter gain in Q2 2026, every quarter in the disclosed series declined from the prior quarter. Q3 2026 revenue was down 28.1% year on year.

10

Risk factors

Subsidiary earnings volatility

Weakness at the subsidiary EWLK drove the Q3 2026 decline. A slump at the subsidiary can push controlling-shareholder net income into a loss, as happened in Q3 2026. Whether the subsidiary's profitability recovers after Q4 is the key item to watch.

Currency translation

Disclosed figures are prepared in US dollars and translated into won at period-average exchange rates. The Q3 2026 average was KRW 1,423.38 per dollar, above KRW 1,385.28 in Q3 2025. Exchange-rate moves change won-denominated revenue and profit figures.

Dividend conditions

The fiscal 2026 year-end dividend is conditional on distributable profit being confirmed. The final amount may fall short of KRW 3 billion. The specific amount and payment date will be set later by a board resolution.

11

What to watch next

  1. December 31, 2026

    KDR dividend record date. Holders seeking reduced withholding rates must transfer balances to a QI account manager before this date, per the disclosure.

  2. Mid-February 2027 (based on last year's timing)

    Provisional Q4 2026 results are expected around this time. The prior-year Q4 provisional results were disclosed on February 20, 2026. Whether the operating margin recovers from the Q3 2026 level is the item to check.

  3. Late March 2027

    Deadline for the fiscal 2026 business report. Full-year operating profit and subsidiary results will be confirmed in final figures.

  4. 2027 annual general meeting

    The fiscal 2026 year-end cash dividend proposal (up to KRW 3 billion) is scheduled for submission and resolution. The final amount and payment date will be set after the board resolution.

12

Overall view

Englewood Lab posted the strongest profitability of the 2022–2025 period in 2025, with operating profit of KRW 35.3 billion and a 17.2% operating margin. However, Q3 2026 operating profit fell to KRW 4.87 billion and the company posted a controlling-shareholder net loss of KRW 1.35 billion.

The subsidiary EWLK, cited as the cause of the decline, carries a large share of group profit, which is central to the current phase. On the balance sheet, the debt-to-equity ratio was 37.9% and total equity KRW 154.2 billion at year-end 2025.

The planned dividend of up to KRW 3 billion signals a shareholder-return direction, but the final amount is not yet set. Valuation sits below book value, yet controlling-shareholder net income of KRW 18.1 billion over the last four quarters means the earnings base has weakened and should be read together with that.

Bull factors include the US production infrastructure and customer response to the RTG OTC service, while bear factors include subsidiary volatility and declining quarterly revenue.

The next checkpoints are the Q4 2026 provisional results, the fiscal 2026 business report and the dividend resolution at the 2027 annual general meeting.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. leadeconomy.co.kr
  2. digitaltoday.co.kr
  3. comp.fnguide.com
  4. beautynury.com
  5. digitaltoday.co.kr
  6. beautynury.com
  7. paxetv.com
  8. news.nate.com
  9. m.news.nate.com
  10. kind.krx.co.kr
  11. vegannews.co.kr
  12. digitaltoday.co.kr
  13. vegannews.co.kr
  14. dailian.co.kr
  15. m.news.nate.com
  16. m.irgo.co.kr
  17. biz.irgo.co.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis